Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards

BREAKING: Pfizer’s COVID-19 vaccine receives European authorization

By Sean Whooley | December 21, 2020

Pfizer BioNTechPfizer (NYSE:PFE) and BioNTech (NSDQ:BNTX) announced today that they received conditional authorization from European regulators.

The European Commission confirmed that it granted a conditional marketing authorization for the vaccine developed by the two companies, making it the first available COVID-19 vaccine in the European Union.

The news follows an earlier announcement that the companies had received a positive opinion from European regulators on their COVID-19 vaccine.

“Today we add an important chapter to a European success story,”  European Commission President Ursula von der Leyen said in the release. “We approved the first safe and effective vaccine against COVID-19. More vaccines will come soon. Doses of the vaccine approved today will be available for all EU countries, at the same time, on the same conditions. The upcoming European vaccination days will also be a great moment of unity.

“This is a good way to end this difficult year, and to start turning the page on this pandemic. We are all in this together.”

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued the positive opinion, recommending CMA of Pfizer and BioNTech’s COVID-19 vaccine in individuals 16 years of age and older, according to a news release.

CHMP advisors based their positive opinion on data from the companies’ Phase 3 clinical study, which included a 95% efficacy rate. The European Commission will review the CHMP recommendation, with a final decision on CMA expected in the near future. CMA would make the vaccine available to all 27 EU member states.

The vaccine was made available in the United Kingdom earlier this month and received FDA emergency use authorization in the U.S. just over a week later.

Pfizer and BioNTech said the vaccine has been authorized or approved for emergency use in more than 15 countries in total, with regulatory reviews underway in several more, as well as further submissions forthcoming.

“Today is a particularly personal and emotional day for us at BioNTech,” BioNTech CEO & co-founder Ugur Sahin said in the release. “Being in the heart of the EU, we are thrilled to be one step closer to potentially delivering the first vaccine in Europe to help combat this devastating pandemic. We are standing by ready to start the delivery of initial vaccine doses across the EU as soon as we get the green light.”

“We are pleased with the Committee’s strong vote of confidence in our data,” added Pfizer chairman & CEO Albert Bourla. “If the European Commission issues an authorization, we are ready to start delivering this vaccine to government-designated sites all across the EU where cases of disease continue to rise and several countries are managing lockdowns.”

 

This story was updated to convey that, following an earlier announcement that the vaccine was positively reviewed, the European Commission granted authorization.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Norway investigating deaths of 23 individuals who received COVID-19 vaccine
Pharma image
Here’s what molecular shape can tell you about pharma innovation
Remdesivir
3 notable types of innovative drugs from 2020
Phastar
Phastar wins investment from Charterhouse Capital Partners

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Drug Discovery and Development
  • Enews Signup
  • Contact Us
  • R&D World
  • Pharmaceutical Processing
  • Drug Delivery Business News

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards